Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs
Precise targeting has become the main direction of anti-cancer drug development. Trophoblast cell surface antigen 2 (Trop-2) is highly expressed in different solid tumors but rarely in normal tissues, rendering it an attractive target. Trop-2-targeted antibody-drug conjugates (ADCs) have displayed p...
Saved in:
Main Authors: | Yizhi Jiang (Author), Haiting Zhou (Author), Junxia Liu (Author), Wentao Ha (Author), Xiaohui Xia (Author), Jiahao Li (Author), Tengfei Chao (Author), Huihua Xiong (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current Status and Future Prospects of TROP-2 ADCs in Lung Cancer Treatment
by: Li M, et al.
Published: (2024) -
Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges
by: Junxia Liu, et al.
Published: (2023) -
Trop2-targeted therapy in breast cancer
by: Yixuan Hu, et al.
Published: (2024) -
Une femme trop gaie
by: Thierry Savatier
Published: (2003) -
Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development
by: Manar Hammood, et al.
Published: (2021)